Cost analysis associated with intramuscular versus oral administration of antiretroviral therapy in the management of human immunodeficiency virus infection
Treating HIV-1 with intramuscular CAB+RPV leads to increased resource consumption and costs, compared to oral ART.
Authors
- Antonio Arjona Castro (ORCID: https://orcid.org/0000-0003-1587-8564)
- Vicente Estrada (ORCID: https://orcid.org/0000-0002-7795-5986)
- Montserrat Pérez-Encinas (ORCID: https://orcid.org/0000-0003-4505-2958)
- María Presa (ORCID: https://orcid.org/0000-0001-5925-0619)
- Laura Salinas-Ortega (ORCID: https://orcid.org/0000-0002-7066-0659)
- Juan Emilio Losa (ORCID: https://orcid.org/0000-0002-0750-0185)
- Ramón Morillo‐Verdugo (ORCID: https://orcid.org/0000-0002-8849-2737)
- Jesús Santos
Institutions
- Hospital Clínico San Carlos (ES)
- Hospital Universitario Fundación Alcorcón (ES)
- Gilead Sciences (Spain) (ES)
- Hospital Universitario de Valme (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Pharmacoeconomics and Health Outcomes Research Iberia (Spain) (ES)
Publication Details
- Journal
- Enfermedades infecciosas y microbiologia clinica (English ed )
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1016/j.eimce.2024.12.003
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences